HC Wainwright Issues Pessimistic Estimate for KZR Earnings

Kezar Life Sciences, Inc. (NASDAQ:KZR) – Equities research analysts at HC Wainwright cut their Q4 2024 EPS estimates for shares of Kezar Life Sciences in a research report issued to clients and investors on Monday, December 2nd. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($2.59) per share for the quarter, down from their previous estimate of ($1.70). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Kezar Life Sciences’ current full-year earnings is ($6.30) per share. HC Wainwright also issued estimates for Kezar Life Sciences’ Q1 2025 earnings at ($2.56) EPS, Q2 2025 earnings at ($2.57) EPS, Q3 2025 earnings at ($2.59) EPS, Q4 2025 earnings at ($2.61) EPS and FY2025 earnings at ($10.33) EPS.

A number of other brokerages have also issued reports on KZR. Wells Fargo & Company decreased their target price on shares of Kezar Life Sciences from $20.00 to $11.00 and set an “equal weight” rating for the company in a research report on Thursday, November 14th. William Blair reaffirmed a “market perform” rating on shares of Kezar Life Sciences in a report on Wednesday, November 13th.

Kezar Life Sciences Stock Performance

Shares of KZR opened at $7.05 on Wednesday. The business’s 50 day moving average is $7.61 and its two-hundred day moving average is $6.77. The firm has a market cap of $51.44 million, a price-to-earnings ratio of -0.53 and a beta of 0.25. Kezar Life Sciences has a 52-week low of $5.20 and a 52-week high of $11.35. The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.05.

Kezar Life Sciences (NASDAQ:KZR) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($2.78) EPS for the quarter, topping the consensus estimate of ($3.03) by $0.25.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Stonepine Capital Management LLC bought a new stake in Kezar Life Sciences in the second quarter worth about $630,000. Acuitas Investments LLC increased its holdings in shares of Kezar Life Sciences by 42.8% in the second quarter. Acuitas Investments LLC now owns 986,785 shares of the company’s stock worth $592,000 after buying an additional 295,956 shares during the period. Ikarian Capital LLC raised its holdings in Kezar Life Sciences by 23.0% in the 3rd quarter. Ikarian Capital LLC now owns 1,068,992 shares of the company’s stock worth $827,000 after purchasing an additional 200,000 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Kezar Life Sciences in the 2nd quarter worth about $63,000. Finally, Geode Capital Management LLC raised its stake in Kezar Life Sciences by 15.0% during the third quarter. Geode Capital Management LLC now owns 626,912 shares of the company’s stock valued at $485,000 after buying an additional 81,678 shares during the last quarter. 67.90% of the stock is owned by institutional investors and hedge funds.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.